Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 39, 2010, Pages 17017-17022

  Liu, Jun Yan ^a   Li, Ning ^b   Yang, Jun ^a   Li, Nan ^c   Qiu, Hong ^b   Ai, Ding ^a,c   Chiamvimonvat, Nipavan ^b   Zhu, Yi ^c   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PEKING UNIVERSITY   (China)

Author keywords

Cardiovascular side effect; Coxib; Eicosanoids; Metabolomics; Vioxx

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 6 OXOPROSTAGLANDIN F1 ALPHA; BIOLOGICAL MARKER; CYTOCHROME P450 4A; INDOMETACIN; PROSTACYCLIN; ROFECOXIB; THROMBOXANE B2; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYICOSATETRAENOIC ACID; LACTONE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; BLEEDING TIME; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG METABOLISM; HEMOSTASIS; IMMUNOREACTIVITY; IN VITRO STUDY; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; ANIMAL; BLOOD; C57BL MOUSE; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG EFFECTS; MALE; THROMBOCYTE;

MURINAE; RATTUS;

ANIMALS; BIOLOGICAL MARKERS; BLEEDING TIME; BLOOD COAGULATION; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; HYDROXYEICOSATETRAENOIC ACIDS; LACTONES; MALE; MICE; MICE, INBRED C57BL; PLATELET AGGREGATION; SULFONES;

EID: 78049297452     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1011278107     Document Type: Article

References (43)

1. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959. (Pubitemid 33010342)
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New Engl J Med 343:1520-1528.
3. Wadman M (2007) Merck settles Vioxx lawsuits for $4.85 billion. Nature 450:324-325.
4. Ray WA, Griffin MR, Stein CM (2004) Cardiovascular toxicity of valdecoxib. N Engl J Med 351:2767.
5. Cheng Y, et al. (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296:539-541. (Pubitemid 34408674)
6. Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351:1709-1711.
7. Schmelzer KR, et al. (2006) Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103:13646-13651.
8. Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 330:1366-1369. (Pubitemid 40839565)
9. Singh G, Wu O, Langhorne P, Madhok R (2006) Risk of acute myocardial infarction with non-selective non-steroidal anti-inflammatory drugs: A meta-analysis. Arthritis Res Ther 8:R153.
10. Helin-Salmivaara A, et al. (2006) NSAID use and the risk of hospitalization for first myocardial infarction in the general population: A nationwide case-control study from Finland. Eur Heart J 27:1657-1663. (Pubitemid 44025350)
11. Johnson AG, Simons LA, Simons J, Friedlander Y, McCallum J (1993) Non-steroidal anti-inflammatory drugs and hypertension in the elderly: A community-based cross-sectional study. Br J Clin Pharmacol 35:455-459. (Pubitemid 23158057)
12. Page J, Henry D (2000) Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem. Arch Intern Med 160:777-784. (Pubitemid 30165238)
13. Reddy LR, Corey EJ (2005) Facile air oxidation of the conjugate base of rofecoxib (Vioxx (TM)), a possible contributor to chronic human toxicity. Tetrahedron Lett 46: 927-929.
14. Brindle JT, et al. (2002) Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8:1439-1444.
15. Lewis GD, et al. (2008) Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 118:3503-3512.
16. Lindon JC, et al. (2005) The Consortium for Metabonomic Toxicology (COMET): Aims, activities and achievements. Pharmacogenomics 6:691-699.
17. Fiehn O (2002) Metabolomics - The link between genotypes and phenotypes. Plant Mol Biol 48:155-171.
18. Wikoff WR, Pendyala G, Siuzdak G, Fox HS (2008) Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J Clin Invest 118:2661-2669. (Pubitemid 351949793)
19. Liu JY, et al. (2010) Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 79:880-887.
20. Yang J, Schmelzer K, Georgi K, Hammock BD (2009) Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 81:8085-8093.
21. Tofler GH, et al. (1987) Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 316:1514-1518. (Pubitemid 17076236)
22. Kovalenko VM, et al. (1991) The blood-coagulation and anticoagulation system and platelet-aggregation at rest and exercise in healthy-persons and patients with coronary heart-disease. Ter Arkh 63:69-71 (in Russian).
23. Hurlen M, Seljeflot I, Arnesen H (2000) Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res 99:487-494.
24. Kalendov Z, Austin J, Steele P (1974) Increased platelet aggregability in young patients with stroke. Neurology 24:373.
25. Milner PC, Martin JF (1985) Shortened bleeding time in acute myocardial infarction and its relation to platelet mass. Br Med J (Clin Res Ed) 290:1767-1770.
26. Dalby Kristensen S, Milner PC, Martin JF (1988) Bleeding time and platelet volume in acute myocardial infarction - A 2 year follow-up study. Thromb Haemost 59:353-356.
27. Sciulli MG, Capone ML, Tacconelli S, Patrignani P (2005) The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacol Rep 57(Suppl):66-85.
28. Powell PK, Wolf I, Jin RY, Lasker JM (1998) Metabolism of arachidonic acid to 20-hydroxy- 5,8,11, 14-eicosatetraenoic acid by P450 enzymes in humanliver: Involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 285:1327-1336.
29. Hill E, Fitzpatrick F, Murphy RC (1992) Biological activity and metabolism of 20- hydroxyeicosatetraenoic acid in the human platelet. Br J Pharmacol 106:267-274.
30. Schwartzman ML, Falck JR, Yadagiri P, Escalante B (1989) Metabolism of 20- hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endothelium-dependent vasoconstrictor metabolites. J Biol Chem 264:11658-11662. (Pubitemid 19185331)
31. Fang X, et al. (2006) 20-Hydroxyeicosatetraenoic acid is a potent dilator of mouse basilar artery: Role of cyclooxygenase. Am J Physiol-Heart C 291:H2301-H2307.
32. Collins XH, et al. (2005) Omega-oxidation of 20-hydroxyeicosatetraenoic acid (20- HETE) in cerebral microvascular smooth muscle and endothelium by alcohol dehydrogenase 4. J Biol Chem 280:33157-33164.
33. Roman RJ, Renic M, Dunn KMJ, Takeuchi K, Hacein-Bey L (2006) Evidence that 20- HETE contributes to the development of acute and delayed cerebral vasospasm. Neurol Res 28:738-749. (Pubitemid 44656100)
34. Miyata N, et al. (2005) Beneficial effects of a new 20- hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4- morpholin-4-yl) phenyl-N′-hydroxyimido formamide], on hemorrhagic and ischemic stroke. J Pharmacol Exp Ther 314:77-85. (Pubitemid 41058243)
35. Kehl F, et al. (2002) 20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat. Am J Physiol-Heart C 282:H1556-H1565.
36. Nithipatikom K, et al. (2004) Inhibition of cytochrome P450omega-hydroxylase: A novel endogenous cardioprotective pathway. Circ Res 95:e65-e71.
37. Escalante B, et al. (1993) 20-hydroxyeicosatetraenoic acid is an endothelium-dependent vasoconstrictor in rabbit arteries. Eur J Pharmacol 235:1-7. (Pubitemid 23124061)
38. Zhu Y, Schieber EB, McGiff JC, Balazy M (1995) Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension 25:854-859.
39. Gislason GH, et al. (2009) Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 169:141-149.
40. Liu JY, et al. (2009) Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol 156:284-296.
41. Bauer C, Corsi C, Paolini M (1994) Stability of microsomal monooxygenases in murine liver S9 fractions derived from phenobarbital and beta-naphthoflavone induced animals under various long-term conditions of storage. Teratog Carcinog Mutagen 14:13-22. (Pubitemid 24069461)
42. Watanabe T, Morisseau C, Newman JW, Hammock BD (2003) In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl- urea. Drug Metab Dispos 31:846-853.
43. Pawloski JR, Swaminathan RV, Stamler JS (1998) Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation. Circulation 97:263-267. (Pubitemid 28067312)